Cerebras Stock Will Ride the AI Wave With Innovation-Driven Growth

Cerebras remains a high-growth AI infrastructure story after its IPO, with revenue rising from $24.6 million in 2022 to $510 million in fiscal 2025 and gross margin at 39%. The company reported $24.6 billion of remaining performance obligations as of December 2025, implying about $3.69 billion of revenue recognition potential over the next 24 months, and it has a $5.7 billion pro forma cash buffer. The stock has corrected from a post-IPO high near $386, but Ark Invest added 124,905 shares in the week ended May 22, reinforcing bullish sentiment.

Analysis

CBRS is behaving like a classic post-IPO de-rating of scarcity value into a still-strong secular story: the first leg was driven by narrative and float scarcity, but the next leg will be about whether bookings convert into durable, repeatable revenue faster than the market can normalize the multiple. The setup favors a selective long only if investors believe the company can keep compounding RPO while holding gross margins near current levels; otherwise the stock is vulnerable to “good business, bad stock” compression once the post-debut excitement fades.

The more important second-order winner here is AMZN. Any credible AWS deployment of specialized AI infrastructure strengthens Amazon’s posture versus pure-play cloud peers by broadening its AI stack without bearing all the R&D risk internally. It also creates an option value path where third-party acceleration hardware becomes a demand magnet for AWS workloads, potentially pulling incremental enterprise and sovereign AI spend into Amazon’s ecosystem rather than into standalone GPU-centric platforms.

The biggest risk is not demand destruction in the macro sense, but customer concentration and execution timing: if a handful of large deals slip by even 1-2 quarters, the market will discount the backlog more aggressively because early-stage AI infrastructure names trade on conversion speed, not just headline RPO. Another subtle risk is competitive response from incumbent GPU vendors and hyperscalers building their own custom silicon economics, which could pressure Cerebras’ pricing power over a 12-24 month horizon. In other words, the stock can work for months on momentum and backlog optics, but the longer-dated debate is whether the product remains differentiated enough to justify premium valuation once the easy narrative premium has been arbitraged away.

The contrarian angle is that the market may already be paying for near-perfect growth execution while underestimating how much of the balance sheet cushion could get consumed by capex, inventory, and continued R&D before profitability inflects. That means the downside is likely slower than shorts want in the near term, but the upside from here is less about multiple expansion and more about proving conversion quality and margin leverage quarter by quarter. If that proof comes through, the stock can re-rate again; if not, the post-IPO bounce may ultimately mark the high-water mark for enthusiasm rather than the start of a multi-year rerating.

Key Decisions for Investors

• Long CBRS on weakness over the next 2-6 weeks only if the stock holds above the post-correction support zone; target a 2:1 reward/risk trade for a rebound tied to backlog conversion updates, but cut quickly if volume fades and the multiple stops compressing.
• Buy AMZN as a secondary beneficiary over a 3-12 month horizon; the asymmetry comes from AWS capturing more AI infrastructure share without a commensurate step-up in internal risk, with upside if Cerebras-like deployments broaden AWS’ AI ecosystem.
• Pair trade: long AMZN / short a basket of GPU-heavy AI infrastructure peers on a 3-6 month view; thesis is that diversified cloud distribution and optionality can outperform pure hardware scarcity names if the market starts rewarding monetization certainty over narrative.
• For higher-conviction traders, consider selling CBRS out-of-the-money puts 1-2 quarters out after volatility settles; the edge is monetizing post-IPO implied vol while expressing a willingness to own only at a materially lower effective basis.
• Set a catalyst watch for the next two earnings cycles: if CBRS shows backlog conversion, margin stability, and no major customer slippage, add; if R&D stays elevated without operating leverage, use any bounce to reduce exposure.